This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Add Allscripts to Your Portfolio Now
by Zacks Equity Research
Allscripts' (MDRX) focus on innovation makes it a worthy investment pick.
MDRX vs. HMSY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MDRX vs. HMSY: Which Stock Is the Better Value Option?
Veeva Systems to Improve Patient Outcome With Crossix Buyout
by Zacks Equity Research
The latest acquisition fortifies Veeva Systems' (VEEV) foothold in the HCIT space further.
NextGen's (NXGN) Population Health Picked by Ohio-Based UH
by Zacks Equity Research
NextGen's (NXGN) EHR services are expected to enhance patient outcomes at UH.
MDRX vs. HMSY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MDRX vs. HMSY: Which Stock Is the Better Value Option?
Is AllScripts Healthcare (MDRX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AllScripts (MDRX) Down 9.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MDRX vs. HMSY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDRX vs. HMSY: Which Stock Is the Better Value Option?
Allscripts Inks Deal With Apple for Electronic Health Record
by Zacks Equity Research
Allscripts (MDRX) is working toward providing compact health records.
Bright Near-Term Outlook for Medical Info Systems Industry
by Sreyoshi Mukherjee
Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.
Allscripts' (MDRX) Veradigm Collaborates With Komodo Health
by Zacks Equity Research
Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.
Here's Why You Should Invest in Cooper Companies Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
MDRX vs. NXGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MDRX vs. NXGN: Which Stock Is the Better Value Option?
Here's Why You Should Invest in HMS Holdings (HMSY) Stock Now
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services as well as robust margins.
Allscripts (MDRX) Q2 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.
AllScripts Healthcare (MDRX) Beats Q2 Earnings Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 6.25% and -0.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AllScripts Healthcare (MDRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MDRX or CERN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MDRX vs. CERN: Which Stock Is the Better Value Option?
MDRX vs. CERN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDRX vs. CERN: Which Stock Is the Better Value Option?
Here's Why You Should Retain Allscripts (MDRX) Stock Now
by Zacks Equity Research
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Ecolab's (ECL) New Digital Dashboards to Improve Healthcare
by Zacks Equity Research
Ecolab's (ECL) Hand Hygiene Compliance Monitoring System connects with digital dashboards.
Why Is AllScripts (MDRX) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.
AllScripts Healthcare (MDRX) Q1 Earnings Surpass Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 14.29% and -1.02%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AllScripts Healthcare (MDRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.